-
公开(公告)号：US12053520B2
公开(公告)日：2024-08-06
申请号：US17587817
申请日：2022-01-28
Inventor： Xuejun Chen , Jeffrey Boyington , Hongying Duan Holdsworth , Cheng Cheng , John R. Mascola
IPC: A61K39/21 , C07K14/005 , C07K14/16 , C12N7/00 , A61K39/00
CPC classification number: A61K39/21 , C07K14/005 , C07K14/162 , C12N7/00 , C12Y205/01078 , A61K2039/5258 , A61K2039/55555 , C07K2319/00 , C12N2740/16023 , C12N2740/16043 , C12N2740/16111 , C12N2740/16122 , C12N2740/16134 , C12N2740/16171
Abstract: Embodiments of immunogens based on the outer domain of HIV-1 gp120 and methods of their use and production are disclosed. Nucleic acid molecules encoding the immunogens are also provided. In several embodiments, the immunogens can be used to prime an immune response to gp120 in a subject, for example, to treat or prevent an HIV-1 infection in the subject.
-
公开(公告)号：US20240197854A1
公开(公告)日：2024-06-20
申请号：US18274943
申请日：2022-01-28
Applicant: Duke University
Inventor： Rory Henderson , Barton F. Haynes
IPC: A61K39/12 , A61K39/00 , A61K39/39 , A61P31/18 , C07K14/005
CPC classification number: A61K39/12 , A61K39/39 , A61P31/18 , C07K14/005 , A61K2039/55555 , A61K2039/575 , C12N2740/16122 , C12N2740/16134
Abstract: This invention provides in general, a composition suitable for use in inducing anti-HIV-1 antibodies, such as immunogenic compositions comprising envelope proteins and nucleic acids to induce cross-reactive neutralizing antibodies and increase their breadth of coverage. The invention also provides methods of inducing such broadly neutralizing anti-HIV-1 antibodies using such compositions.
-
公开(公告)号：US20230374078A1
公开(公告)日：2023-11-23
申请号：US18342949
申请日：2023-06-28
Applicant: Janssen Vaccines & Prevention B.V.
Inventor： Johannes Petrus Maria LANGEDIJK , Lucy RUTTEN , Nika Mindy STROKAPPE , Daphné TRUAN
IPC: C07K14/005 , A61K39/12
CPC classification number: C07K14/005 , A61K39/12 , C12N2740/16122 , C12N2740/16134 , A61K2039/55555
Abstract: Human immunodeficiency virus (HIV) envelope proteins having specified mutations that stabilize the trimeric form of the envelope protein are provided. The HIV envelope proteins described herein have an improved percentage of trimer formation and/or an improved trimer yield. Also provided are particles displaying the HIV envelope proteins, nucleic acid molecules and vectors encoding the HIV envelope proteins, as well as compositions containing the HIV envelope proteins, particles, nucleic acid, or vectors.
-
公开(公告)号：US20230312658A1
公开(公告)日：2023-10-05
申请号：US18067525
申请日：2022-12-16
Applicant: Centivax, Inc.
Inventor： Jacob E. Glanville
IPC: C07K14/005 , A61K39/12 , A61K39/21 , A61K38/46 , G16B30/10 , A61K39/00 , G16C20/60 , C12N7/00 , G16B35/00 , G16B20/30 , G16B30/00 , G16B35/10 , G16B20/00
CPC classification number: C07K14/005 , A61K38/46 , A61K39/0011 , A61K39/12 , A61K39/21 , C12N7/00 , G16B20/30 , G16B30/00 , G16B30/10 , G16B35/00 , G16B35/10 , G16C20/60 , A61K2039/515 , A61K2039/5154 , A61K2039/53 , A61K2039/575 , A61K2039/70 , C12N2740/16034 , C12N2740/16071 , C12N2740/16122 , C12N2740/16134 , C12N2760/16122 , C12N2760/16134 , C12Y306/05002 , G16B20/00
Abstract: The present disclosure provides compositions and methods for the generation of an antibody or immunogenic composition, such as a vaccine, through epitope focusing by variable effective antigen surface concentration. Generally, the composition and methods of the disclosure comprise three steps: a “design process” comprising one or more in silico bioinformatics steps to select and generate a library of potential antigens for use in the immunogenic composition; a “formulation process”, comprising in vitro testing of potential antigens, using various biochemical assays, and further combining two or more antigens to generate one or more immunogenic compositions; and an “administering” step, whereby the immunogenic composition is administered to a host animal, immune cell, subject or patient. Further steps may also be included, such as the isolation and production of antibodies raised by host immune response to the immunogenic composition.
-
公开(公告)号：US11767347B2
公开(公告)日：2023-09-26
申请号：US17553070
申请日：2021-12-16
Applicant: The Scripps Research Institute
Inventor： Leopold Kong , Ian A. Wilson , Natalia De Val , Andrew B. Ward , Dennis Burton , Linling He , Jiang Zhu
CPC classification number: C07K14/162 , A61K39/21 , A61K47/6929 , C07K14/005 , A61K39/12 , A61K47/64 , A61K2039/5258 , A61K2039/6031 , A61K2039/645 , C12N2740/16122 , C12N2740/16134
Abstract: The present invention provides HIV-1 vaccine immunogens. Some of the immunogens contain a soluble gp140-derived protein that harbors a modified N-terminus of the HR1 region in gp41. Some of the immunogens contain an HIV-1 Env-derived trimer protein that is presented on a nanoparticle platform. The invention also provides methods of using the HIV-1 vaccine immunogens for eliciting an immune response or treating HIV infections.
-
公开(公告)号：US11690906B2
公开(公告)日：2023-07-04
申请号：US17096579
申请日：2020-11-12
Applicant: University of Massachusetts
Inventor： Shan Lu , Shixia Wang
CPC classification number: A61K39/21 , A61K39/12 , A61K45/06 , C07K14/005 , C12N7/00 , H05K999/99 , A61K2039/53 , A61K2039/54 , A61K2039/545 , A61K2039/575 , A61K2039/70 , C12N2740/16134
Abstract: Polyvalent, primary isolate nucleic acid compositions for inducing an immune response against HIV are disclosed. The compositions and methods described herein are for the use of a nucleic acid composition that encodes one or more different HIV envelope glycoproteins. The synthetic, codon-optimized DNAs encoding one or more HIV proteins are a combination of different nucleic acids, such as DNA plasmids, generated from primary isolate DNA of different HIV major group genetic clades and/or different proteins. HIV polypeptide compositions for inducing an immune response against HIV are also disclosed. Methods for using the polypeptide compositions before, at the same time as, and/or after administration of the DNA compositions are provided.
-
公开(公告)号：US10076567B2
公开(公告)日：2018-09-18
申请号：US15024600
申请日：2014-09-29
Applicant: Duke University , Los Alamos National Security, LLC
Inventor： Barton F. Haynes , Bette T. Korber , S. Munir Alam
IPC: A61K39/21 , A61K38/16 , A61K38/21 , A61K9/127 , A61K9/00 , A61K39/12 , A61K47/48 , C07K14/005 , A61K39/39 , C12N7/00 , A61K39/00
CPC classification number: A61K39/21 , A61K9/0019 , A61K9/127 , A61K38/162 , A61K38/212 , A61K39/12 , A61K39/39 , A61K47/6911 , A61K2039/545 , A61K2039/55555 , A61K2039/55572 , A61K2039/575 , C07K14/005 , C12N7/00 , C12N2740/16022 , C12N2740/16034 , C12N2740/16122 , C12N2740/16134 , A61K2300/00
Abstract: The present invention relates to peptides and compositions suitable for use in inducing anti-HIV-1 antibodies. The compositions comprise HIV-1 gp41 membrane proximal external region (MPER) peptide-liposome conjugates for induction of broadly reactive anti-HIV-1 antibodies. The invention also relates to methods of inducing neutralizing anti-HIV-1 antibodies using such compositions.
-
公开(公告)号：US10071153B2
公开(公告)日：2018-09-11
申请号：US12688862
申请日：2010-01-16
Applicant: Michael Ruff , Candace Pert
Inventor： Michael Ruff , Candace Pert
IPC: A61K39/21 , A61K38/16 , C07K14/005 , C07K16/10 , A61K39/12
CPC classification number: A61K39/21 , A61K38/162 , A61K39/12 , C07K14/005 , C07K16/1063 , C07K2317/76 , C12N2740/15022 , C12N2740/16122 , C12N2740/16134
Abstract: Compositions are disclosed that induce broadly HIV therapeutic and vaccine inducing antibodies against diverse HIV clades and relate to the ability to identify HIV gp120-derived short peptide sequence immunogens and various therapeutic compositions made from the identified peptides which compose CCR5 binding sites. Also disclosed are methods of selecting peptide sequences that are likely candidates for drugs which will offer effective treatment in such areas as Alzheimer's disease, psoriasis, multiple sclerosis and other diseases associated with the human inflammatory cascade as well as related retroviruses such as HTLV-1, the cause of tropical spastic paraparesis.
-
公开(公告)号：US20180194809A1
公开(公告)日：2018-07-12
申请号：US15844753
申请日：2017-12-18
Inventor： William Schief , Sergey Menis , Daniel Kulp , Joseph Jardine
IPC: C07K14/005 , C12N7/00 , C12N9/10 , A61K39/21 , A01K67/027 , A61K49/00
CPC classification number: C07K14/005 , A01K67/0278 , A01K2207/15 , A01K2217/072 , A01K2227/105 , A01K2267/03 , A61K39/12 , A61K39/21 , A61K49/0008 , C07K2319/00 , C07K2319/21 , C12N7/00 , C12N9/1085 , C12N2740/16122 , C12N2740/16134 , C12N2740/16171 , C12Y205/01078
Abstract: The present invention relates to engineered outer domain (eOD) immunogens of HIV gp120 and mutants thereof and methods of making and using the same. The present invention also includes fusions of eOD to various protein multimers to enhance immunogenicity. The mutant eODs bind to neutralizing antibody precursors. The mutant eODs can activate germline precursors on the pathway to eliciting a broadly neutralizing antibody (bnAb) response. The invention also relates to immunized knock-in mice expressing germline-reverted heavy chains. Induced antibodies showed characteristics of bnAbs and mutations that favored binding to near-native HIV-1 gp120 constructs. In contrast, native-like immunogens failed to activate precursors. The invention also relates to rational epitope design that can prime rare B cell precursors for affinity maturation to desired targets.
-
公开(公告)号：US09969782B2
公开(公告)日：2018-05-15
申请号：US14508669
申请日：2014-10-07
Applicant: New York University
Inventor： Timothy Cardozo
CPC classification number: C07K14/28 , A61K39/12 , A61K39/21 , A61K2039/6037 , C07K16/1063 , C07K2317/21 , C07K2317/34 , C07K2317/76 , C07K2319/33 , C07K2319/55 , C12N2740/16134
Abstract: The present invention relates to an isolated immunogenic peptide chimera comprising a first peptide moiety comprising the amino acid sequence of SEQ ID NO: 1, or at least a contiguous 5 amino acid fragment thereof, a second peptide moiety comprising the amino acid sequence of SEQ ID NO: 2, or at least a contiguous 5 amino acid fragment thereof, and a linker joining the first and second peptide moieties, wherein the first peptide moiety is at the immunogenic peptide chimera's N-terminus and the second peptide moiety is at the immunogenic peptide chimera's C-terminus. Also disclosed is an immunogenic peptide including the amino acid sequence corresponding to SEQ ID NO: 6, or at least a contiguous 5 amino acid fragment thereof, having a length sufficient to form β-hairpin structure. A further aspect of the present invention is an immunogenic peptide including the amino acid sequence corresponding to SEQ ID NO: 15, or at least a contiguous 5 amino acid fragment thereof, capable of folding into an alpha-helical structure. These immunogenic peptides can be inserted into an immunogenic scaffold protein to form an immunogenic polypeptide. The immunogenic peptides or immunogenic polypeptides can be used in an immunogenic vaccine composition and in methods of inducing a neutralizing antibody response, or inducing a protective and non-neutralizing antibody response, or protective antibodies, against HIV-1 gp120 in a subject. Isolated antibodies and methods of detecting are also disclosed.
